Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA · Healthcare

₹1,860.00+1.69%06 Nov 2026

Ask the data

Instant answers about Sun Pharmaceutical Industries Ltd. — computed from its filings, no language model

Market cap₹4,46,270 cr

Current price₹1,860.00

High / Low₹2,001 / ₹1,589

P/E40.7

P/B5.00

Book value₹372.1

ROE12.3%

ROCE16.7%

Debt / equity0.03

Dividend yield0.88%

EPS (TTM)₹45.71

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	26,489	29,066	32,838	33,498	38,654	43,886	48,497	52,578	58,462
EBITDA	5,608	6,308	6,990	8,491	10,398	11,647	13,023	15,272	17,731
Operating margin	21.2%	21.7%	21.3%	25.3%	26.9%	26.5%	26.9%	29.0%	30.3%
Interest	518	555	303	141	127	172	238	231	339
Depreciation	1,500	1,753	2,053	2,080	2,144	2,529	2,557	2,575	2,938
Profit before tax	3,479	3,810	5,010	2,799	4,481	9,408	11,088	13,752	15,119
Tax	845	601	823	515	1,076	848	1,439	2,772	3,554
Net profit	2,162	2,665	3,765	2,904	3,273	8,474	9,576	10,929	11,479
EPS ₹	9.00	11.11	15.69	12.10	13.60	35.30	39.90	45.60	47.80
Operating cash flow	—	—	—	—	8,985	4,959	12,135	14,072	12,419
Capex	—	—	—	—	1,495	2,086	2,202	2,129	3,609
Dividend paid	—	—	—	—	2,169	2,520	2,901	3,617	3,938
Total assets	64,516	64,694	68,252	67,667	69,800	80,744	85,463	92,101	1,08,785
Equity	38,314	41,409	45,264	46,463	48,011	55,995	63,667	72,218	83,570

Quarterly performance

last 35 quarters · ₹ crore

showing latest 8 of 35 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	6,977	7,224	6,938	7,740	7,164	8,374	8,123	8,155	8,185	7,585	8,553	8,837	8,523	9,719	9,626	9,863	9,447	10,762	10,952	11,241	10,931	11,941	12,192	12,381	11,983	12,653	13,291	13,675	12,959	13,851	14,478	15,521	14,612	15,300	16,199
Operating profit	1,683	1,607	1,531	2,153	1,017	1,996	1,790	1,841	1,363	1,844	2,193	2,406	2,048	2,821	2,630	2,606	2,340	2,884	2,957	3,004	2,802	3,332	3,179	3,477	3,035	3,608	3,939	4,009	3,716	4,302	4,527	4,948	3,954	4,418	4,744
Operating margin	24.1%	22.2%	22.1%	27.8%	14.2%	23.8%	22.0%	22.6%	16.7%	24.3%	25.6%	27.2%	24.0%	29.0%	27.3%	26.4%	24.8%	26.8%	27.0%	26.7%	25.6%	27.9%	26.1%	28.1%	25.3%	28.5%	29.6%	29.3%	28.7%	31.1%	31.3%	31.9%	27.1%	28.9%	29.3%
Other income	303	200	351	193	282	213	201	120	102	154	256	315	111	153	223	433	114	2	85	174	373	204	294	250	606	533	354	466	613	464	470	579	458	724	517
Interest	155	131	130	145	150	104	84	63	52	52	33	26	30	35	36	19	37	14	19	46	93	81	49	35	74	62	69	52	49	75	100	78	86	100	75
Depreciation	455	402	427	471	454	457	473	547	575	496	499	532	553	503	530	554	556	588	610	660	672	651	633	622	650	655	626	631	664	701	730	732	775	739	758
Profit before tax	1,376	1,274	112	1,730	694	1,647	1,433	1,351	577	-2,184	1,917	2,163	903	1,804	2,287	2,466	-2,076	2,285	2,412	2,471	2,240	2,481	2,791	3,000	2,816	3,424	3,598	3,476	3,254	3,173	4,168	4,227	3,551	4,099	3,159
Tax	-177	164	219	271	-29	146	266	328	83	246	-31	245	55	396	198	335	147	189	152	283	223	468	390	432	149	552	567	559	1,094	870	1,031	826	828	1,188	1,158
Net profit	1,309	1,111	-219	1,242	636	1,387	1,064	914	400	-1,656	1,813	1,852	894	1,444	2,047	2,059	-2,277	2,061	2,262	2,166	1,984	2,023	2,376	2,524	2,655	2,836	3,040	2,903	2,150	2,279	3,118	3,369	2,714	2,895	1,989
EPS ₹	5.50	4.09	-0.91	5.18	2.65	5.78	4.43	3.81	1.67	-6.90	7.56	7.72	3.70	6.00	8.50	8.60	-9.50	8.60	9.40	9.00	8.30	8.40	9.90	10.50	11.10	11.80	12.70	12.10	9.00	9.50	13.00	14.00	11.30	12.10	8.30
Revenue YoY	—	—	—	—	2.7%	15.9%	17.1%	5.4%	14.3%	-9.4%	5.3%	8.4%	4.1%	28.1%	12.5%	11.6%	10.8%	10.7%	13.8%	14.0%	15.7%	11.0%	11.3%	10.1%	9.6%	6.0%	9.0%	10.5%	8.1%	9.5%	8.9%	13.5%	12.8%	10.5%	11.9%
Profit YoY	—	—	—	—	-51.4%	24.9%	—	-26.4%	-37.1%	-219.3%	70.4%	102.8%	123.6%	—	12.9%	11.1%	-354.7%	42.7%	10.5%	5.2%	—	-1.9%	5.0%	16.5%	33.8%	40.2%	28.0%	15.0%	-19.0%	-19.6%	2.6%	16.0%	26.2%	27.0%	-36.2%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Sun Pharmaceutical Industries Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	3,140	4,011	3,698	2,763	3,483	7,612	7,760
Operating profit	1,321	1,809	845	417	-1,004	-220	95
Operating margin	42.1%	45.1%	22.9%	15.1%	-28.8%	-2.9%	1.2%
Other income	71	172	185	103	218	217	514
Interest	126	121	1	3	123	531	224
Depreciation	64	76	86	101	480	464	419
Profit before tax	1,454	2,026	943	416	-1,390	-1,068	-32
Tax	70	98	146	116	-949	5	3
Net profit	1,384	1,928	796	301	-441	-1,073	-35

Quarters

showing latest 8 of 40 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	JUN '09†	SEP '09†	DEC '09†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	541	734	582	671	929	863	477	664	702	759	808	761	812	863	939	1,012	1,197	1,005	1,035	877	781	618	678	690	776	576	597	565	1,745	2,040	1,821	1,854	1,898	1,778	2,029	1,935	2,017	1,803	1,824	2,045
Operating profit	-21	152	21	41	324	240	97	265	318	311	337	324	350	387	417	425	579	357	327	94	68	124	76	72	144	30	-195	-24	-815	-55	-164	98	-99	-68	4	-20	179	-173	-84	178
Operating margin	-3.9%	20.8%	3.7%	6.1%	34.9%	27.8%	20.3%	39.8%	45.3%	41.0%	41.7%	42.5%	43.0%	44.9%	44.4%	42.0%	48.4%	35.5%	31.6%	10.7%	8.7%	20.1%	11.2%	10.4%	18.6%	5.2%	-32.6%	-4.3%	-46.7%	-2.7%	-9.0%	5.3%	-5.2%	-3.8%	0.2%	-1.0%	8.9%	-9.6%	-4.6%	8.7%
Other income	233	226	248	261	30	4	15	-63	13	33	11	11	16	38	13	-71	192	-21	115	34	57	-35	-35	69	103	84	-57	-23	213	-18	-143	28	350	126	294	78	16	26	892	33
Interest	—	—	—	—	30	33	32	31	21	17	32	39	39	41	44	36	0	0	0	0	0	0	0	0	2	8	4	0	111	133	173	157	68	101	7	114	1	83	130	65
Depreciation	14	14	15	14	15	14	17	17	15	18	12	18	16	18	18	20	20	21	22	23	20	24	25	25	27	46	68	41	325	110	120	115	120	105	103	104	107	109	105	106
Profit before tax	198	365	255	288	310	257	126	216	338	343	368	354	389	449	455	370	751	315	419	104	104	66	17	116	218	60	-323	-88	-1,038	-385	-600	-145	62	-148	187	-160	88	-1,290	574	41
Tax	3	19	7	7	7	0	5	13	20	20	22	12	16	26	18	5	49	22	49	30	45	20	11	30	55	12	-5	3	-959	2	2	2	1	3	3	3	-6	1	-3	1
Net profit	195	346	248	281	303	257	122	203	318	323	346	343	373	423	438	365	702	293	371	74	59	46	6	86	163	48	-318	-91	-79	-387	-601	-147	62	-151	185	-163	95	-1,291	577	40
EPS ₹	9.80	17.20	12.20	13.60	14.60	12.40	5.90	9.80	15.40	15.60	16.70	3.30	3.60	4.10	4.20	3.50	6.80	2.80	3.60	0.70	0.60	0.20	0.03	0.41	0.79	0.23	-1.53	-0.44	-0.30	-1.60	-2.50	-0.60	0.30	-0.60	0.80	-0.70	0.40	-5.40	2.40	0.20
Revenue YoY	—	—	—	—	71.7%	17.6%	-28.9%	-28.5%	-18.6%	59.1%	21.7%	8.3%	—	13.7%	16.2%	33.0%	47.4%	16.5%	10.3%	-13.4%	-34.8%	-38.6%	-34.5%	-21.3%	-0.6%	-6.8%	-11.9%	-18.1%	124.8%	254.3%	204.7%	228.2%	8.7%	-12.8%	11.5%	4.4%	6.3%	1.4%	-10.1%	5.7%
Profit YoY	—	—	—	—	55.6%	-25.8%	-56.7%	-33.0%	23.9%	165.5%	70.3%	7.7%	—	31.2%	26.6%	6.6%	88.3%	-30.9%	-15.3%	-79.7%	-91.6%	-84.4%	-98.3%	15.7%	176.1%	4.1%	-5141.6%	-206.1%	-148.7%	-913.9%	—	—	—	—	—	—	53.3%	—	212.7%	—

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 32 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	9.0%	6.7%	7.4%	10.5%	9.7%	8.3%	1.6%	3.2%	5.3%	6.2%	12.9%	13.4%	13.9%	6.8%	8.1%	7.7%	7.9%	15.1%	15.1%	14.3%	14.9%	15.0%	16.3%	16.0%	16.5%	15.1%	14.4%	13.4%	14.0%	13.7%	14.5%	12.3%
ROCE	10.5%	8.5%	9.2%	11.7%	10.8%	10.1%	2.7%	3.5%	5.0%	5.9%	13.8%	14.6%	15.2%	9.4%	10.4%	9.1%	9.2%	15.4%	15.8%	16.7%	17.6%	17.0%	18.4%	18.4%	19.1%	18.9%	18.6%	17.4%	18.3%	17.6%	18.7%	16.7%
Net margin	11.9%	9.5%	10.1%	13.8%	12.6%	11.5%	2.3%	4.5%	7.3%	8.7%	16.8%	17.0%	17.1%	8.5%	9.8%	10.0%	9.9%	19.3%	18.7%	18.5%	18.8%	19.7%	21.1%	22.0%	22.2%	20.8%	19.3%	19.0%	19.2%	19.6%	20.2%	17.8%
EBITDA margin	24.1%	21.7%	22.2%	22.1%	20.9%	21.3%	21.3%	22.3%	23.5%	25.3%	26.6%	27.0%	26.8%	26.9%	26.4%	26.3%	26.4%	26.5%	26.8%	26.6%	27.0%	26.9%	27.0%	27.9%	28.3%	29.0%	29.7%	30.1%	30.8%	30.3%	29.8%	29.3%
Debt / equity	0.25	0.24	0.24	0.24	0.24	0.17	0.17	0.17	0.17	0.08	0.08	0.08	0.08	0.02	0.02	0.07	0.07	0.11	0.11	0.02	0.02	0.04	0.04	0.03	0.03	0.03	0.03	0.06	0.06	0.05	0.05	0.03
Interest coverage	9.01	7.86	8.92	12.40	13.78	17.55	5.70	9.31	16.17	20.79	55.49	57.25	63.11	36.19	47.83	57.92	44.68	55.70	41.16	38.10	41.80	47.50	55.90	54.71	53.05	60.44	56.19	52.11	50.05	45.61	45.11	45.41
Asset turnover	0.45	0.45	0.47	0.49	0.49	0.48	0.47	0.48	0.49	0.50	0.53	0.54	0.56	0.55	0.57	0.55	0.57	0.54	0.56	0.58	0.60	0.57	0.58	0.57	0.59	0.57	0.58	0.53	0.55	0.54	0.55	0.54

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 18 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	207	207	241	240	240	240	240	240	240	240	240	240	240	240	240	240	240	240
Other equity / reserves	18,525	25,623	32,742	36,400	38,074	41,169	45,025	46,223	47,771	52,878	55,755	59,586	63,427	68,875	71,978	77,580	83,330	89,040
Total equity	18,732	25,830	32,982	36,640	38,314	41,409	45,264	46,463	48,011	53,118	55,995	59,826	63,667	69,115	72,218	77,820	83,570	89,280
Borrowings	2,489	7,596	8,316	8,091	9,752	9,893	7,578	3,523	931	3,807	6,198	1,488	2,846	2,081	1,870	4,686	4,082	2,693
Current liabilities	—	—	13,144	17,887	19,864	17,340	15,706	16,146	17,201	16,701	19,906	15,023	16,984	17,255	18,194	23,415	22,622	23,592
Non-current liabilities	—	—	5,319	3,093	2,454	2,632	3,421	2,041	1,533	1,390	1,521	1,221	1,373	1,481	1,420	2,165	2,283	1,683
Total assets	29,371	48,798	55,530	61,410	64,516	64,694	68,252	67,667	69,800	74,455	80,744	79,441	85,463	88,116	92,101	1,03,706	1,08,785	1,14,838
Property, plant & equipment	3,498	6,975	7,583	8,495	9,159	10,027	10,567	10,235	10,371	10,531	10,390	10,101	10,192	10,098	10,036	10,407	11,114	11,141
Capital work-in-progress	842	1,532	1,203	1,565	1,434	911	659	937	798	806	963	1,017	1,108	1,150	1,234	1,355	1,381	1,864
Investments	2,786	2,716	1,830	1,192	7,143	7,903	10,143	9,612	12,849	13,257	14,830	12,868	15,026	17,744	18,354	19,543	24,723	16,449
Inventories	3,123	5,668	6,423	6,833	6,881	7,886	7,875	8,997	8,997	9,875	10,513	9,956	9,868	9,936	10,243	10,442	11,493	12,592
Receivables	2,200	5,106	6,776	7,203	7,815	8,884	9,421	9,061	10,593	12,201	11,439	11,303	11,249	12,942	13,046	15,396	15,510	17,805
Cash & equivalents	7,590	10,998	8,075	8,663	7,925	7,062	5,677	6,273	4,508	4,296	4,624	5,403	9,286	8,013	10,269	10,022	9,771	18,401

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 12 periods

	FY14‡	FY15‡	FY16‡	FY17‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	3,959	5,616	6,686	7,082	2,196	6,555	6,170	8,985	4,959	12,135	14,072	12,419
Cash from investing	-2,367	-2,866	-4,372	-4,222	-681	-2,589	536	-5,725	-7,944	-690	-5,306	-11,344
Cash from financing	507	-1,187	-1,889	-2,285	-2,731	-5,715	-5,980	-5,193	2,376	-6,710	-7,906	-2,513
Capex	—	8	3,404	3,693	3,213	1,542	1,170	1,495	2,086	2,202	2,129	3,609
Free cash flow	—	5,608	3,282	3,389	-1,016	5,013	5,000	7,490	2,874	9,933	11,944	8,810
Dividends paid	518	310	722	240	480	1,379	1,559	2,169	2,520	2,901	3,617	3,938

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹11,141 cr10%

CWIP

₹1,864 cr2%

Investments

₹16,449 cr14%

Inventories

₹12,592 cr11%

Receivables

₹17,805 cr16%

Cash & equivalents

₹18,401 cr16%

Other assets

₹36,586 cr32%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%

StoxGud checklist: Bullish setup · 8/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+4.4%

6 months+1.4%

1 year+8.4%

3Y CAGR+17.4%

5Y CAGR+18.4%

10Y CAGR+11.0%

50-day avg₹1,824.09

200-day avg₹1,810.60

RSI (14)77

Long-term financials (FY06–FY16)

from published annual reports

Year	Revenue	Profit before tax	Net profit
FY16	₹28,518 Cr	₹6,765 Cr	₹1,113 Cr
FY15	₹27,718 Cr	₹6,403 Cr	₹936 Cr
FY14	₹16,275 Cr	₹4,581 Cr	₹3,141 Cr
FY13	₹11,470 Cr	₹4,321 Cr	₹2,983 Cr
FY12	₹8,127 Cr	₹3,356 Cr	₹2,657 Cr
FY11	₹5,807 Cr	₹2,036 Cr	₹1,816 Cr
FY10	₹4,180 Cr	₹1,415 Cr	₹1,351 Cr
FY09	₹4,375 Cr	₹1,949 Cr	₹1,818 Cr
FY08	₹3,461 Cr	₹1,599 Cr	₹1,487 Cr
FY07	₹2,237 Cr	₹833 Cr	₹784 Cr
FY06	₹1,738 Cr	₹597 Cr	₹573 Cr

Years before FY17 follow the older Indian GAAP standard, so they are not exactly comparable with recent years.

Compare Sun Pharmaceutical Industries Ltd. with

Sun Pharmaceutical Industries vs Divi's Laboratories Sun Pharmaceutical Industries vs Torrent Pharmaceuticals Sun Pharmaceutical Industries vs Laurus Labs Sun Pharmaceutical Industries vs Apollo Hospitals Enterprise

FAQs

What is the share price of Sun Pharmaceutical Industries Ltd.?

Sun Pharmaceutical Industries Ltd. (SUNPHARMA) closed at ₹1,860.00 on NSE on 06 Nov 2026.

What is the market cap of Sun Pharmaceutical Industries Ltd.?

₹4,46,270 crore at the latest close.

What is the P/E ratio of Sun Pharmaceutical Industries Ltd.?

40.7, on trailing-twelve-month earnings from its filings.

How fast is Sun Pharmaceutical Industries Ltd. growing?

Sun Pharmaceutical Industries Ltd.: revenue has compounded at 10.0% a year over three years; net profit at 10.6% a year. Latest-quarter revenue is up 11.9% year on year, profit down 36.2%.

How profitable is Sun Pharmaceutical Industries Ltd.?

On a trailing-twelve-month basis return on equity is 12.3%, return on capital employed 16.7%, operating margin 29.3%, net margin 17.8%.

How much debt does Sun Pharmaceutical Industries Ltd. have?

Sun Pharmaceutical Industries Ltd. is debt-free: debt to equity is 0.03 with borrowings of ₹2,693 cr against cash of ₹18,401 cr (balance sheet of 2026-09-30). Operating profit covers interest 45.4 times.

Financials parsed from Sun Pharmaceutical Industries Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.